Sparfloxacin versus cefaclor in the treatment of patients with community-acquired pneumonia: A randomized, double-masked, comparative, multicenter study

Clinical Therapeutics

Volumn 19, Issue 5, 1997, Pages 936-953

  Donowitz, Gerald R ^a,e   Brandon, Milan L ^b   Salisbury, John P ^c   Harman, Colleen P ^a   Tipping, Diane M ^d   Urick, Ann E ^d   Talbot, George H ^d  

^a UNIVERSITY OF VIRGINIA   (United States)

^b California Research Foundation   (United States)

^c Eatontown Medical Association   (United States)

^d SANOFI   (France)

^e UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Anti infective agents; Bacterial pneumonia; Fluoroquinolone; Spaffloxacin

Indexed keywords

CEFACLOR; CEPHALOSPORIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN;

ADULT; AGED; ARTICLE; BACTERIAL INFECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HUMAN; LUNG INFECTION; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; STREPTOCOCCUS PNEUMONIAE; SUPERINFECTION; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0030703579     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(97)80047-1     Document Type: Article

References (31)

1. National Center for Health Statistics. In-patient utilization of short-stay hospital by diagnosis. US 1982 annual summary. USDHHS data from the National Health Series. Series 13, no. 72 (PHS-83-1733). Washington, DC: National Center for Health Statistics; 1983.
2. Statistical Abstract of the US. 108th ed. Washington, DC: US Department of Commerce, Bureau of Census; 1988.
3. Musher DM, Spindel SJ. Community-acquired pneumonia. Curr Clin Top Infect Dis. 1996;16:102-124.
4. Fang GD, Fine M, Orloff J, et al. New and emerging etiologies for communityacquired pneumonia with implications for therapy: A prospective multicenter study of 359 cases. Medicine. 1990;69:307-315.
5. Marrie TJ. Community-acquired pneumonia. Clin Infect Dis. 1994; 18:501-515.
6. Schwarzmann SW, Adler JL, Sullivan RJ, et al. Bacterial pneumonia during the Hong Kong influenza epidemic of 1968-1969. Experience in a city-county hospital. Arch Intern Med. 1971;127:1037-1041.
7. Marrie TJ, Peeling RW, Fine MJ, et al. Ambulatory patients with community-acquired pneumonia: The frequency of atypical agents and clinical course. Am J Med. 1996;101:508-515.
8. Woodhead MA, MacFarlane JT. Comparative clinical and laboratory features of Legionella with pneumococcal and Mycoplasma pneumonias. Br J Dis Chest. 1987;81:133-139.
9. Fair BM, Kaiser DL, Harrison BDW, Connolly CK. Prediction of microbial aetiology at admission to hospital for pneumonia from the presenting clinical features. Thorax. 1989;44:1031-1035.
10. American Thoracic Society. Guidelines for the initial management of adults with community-acquired pneumonia: Diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis. 1993;148:1418-1426.
11. Breiman RF, Butler JC, Tenover FC, et al. Emergence of drug-resistant pneumococcal infections in the United States. JAMA. 1994;271:1831-1835.
12. Friedland IR, McCracken JR. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. NEJM. 1994;331:377-382.
13. Malmborg AS, Ahlén S. In vitro activity of sparfloxacin compared with ciprofloxacin and ofloxacin against respiratory tract pathogens. Chemotherapy. 1993;39:32-35.
14. Barry AL, Fuchs PC. In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin. Antimicrob Agents Chemother. 1991;35:955-960.
15. Wise R, Honeybourne A. Review of the penetration of sparfloxacin into the lower respiratory tract and sinuses. J Antimicrob Chemother. 1996;37(Suppl A):57-63.
16. Aubier M, Lode H, Gialdroni-Grassi G, et al. Sparfloxacin for the treatment of community-acquired pneumonia: A pooled data analysis of two studies. J Antimicrob Chemother. 1996;37(Suppl A):73-82.
17. Portier H, May TL, Proust A, and the French Study Group. Comparative efficacy of sparfloxacin in comparison with amoxycillin plus ofloxacin in the treatment of community-acquired pneumonia. J Antimicrob Chemother. 1996;37(Suppl A):83-91.
18. Lode H, Garau J, Grassi C, et al. Treatment of community-acquired pneumonia: A randomized comparison of sparfloxacin, amoxycillin-clavulanic acid and erythromycin. Eur Respir J. 1995;8:1999-2007.
19. Ortquist A, Valtanen M, Cars O, et al. Oral empiric treatment of community-acquired pneumonia: A multicenter, double-blind, randomized study comparing sparfloxacin and roxithromycin. Chest. 1996;110: 1499-1506.
20. Jaillon P, Morganroth J, Brumpt I, and the Sparfloxacin Safety Group. Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. J Antimicrob Chemother. 1996;37(Suppl A): 161-167.
21. Marrie TJ, Durant H, Yates L. Community-acquired pneumonia requiring hospitalisation. 5 Year prospective study. Rev Infect Dis. 1989;11:586-599.
22. Bates JH, Campbell GD, Barren AL, et al. Microbial etiology of acute pneumonia in hospitalized patients. Chest. 1992;101: 1005-1012.
23. Khan FA. Ciprofloxacin for respiratory tract infection. In: Sanders EW, Sanders CL, eds. Fluoroquinolones in the Treatment of Infectious Diseases. Glenview. III: Physicians and Scientists Publishing; 1990:87-88.
24. Klein NC. Fluoroquinolones in respiratory infections. Semin Respir Infect. 1991; 6:131-135.
25. Davies BI, Maesen FP, Baur C. Ciprofloxacin in the treatment of acute exacerbations of chronic bronchitis. Eur J Clin Microbiol 1986;5:226-231.
26. Jones RN, Relier LB, Rosati LA, et al. Ofloxacin, a new broad-spectrum fluoroquinolone. Results from a multicenter national comparative activity surveillance study. The ofloxacin surveillance group. Diagn Microbiol Infect Dis. 1992;15: 425-434.
27. Kimura M, Kishimoto T, Niki Y, Soejima R. In vitro and in vivo antichlamydial activities of newly developed quinolone antimicrobial agents. Antimicrob Agents Chemother. 1993;37:801-803.
28. Soejima R, Niki Y, Kishimoto T, et al. Antichlamydial activities of newly developed fluoroquinolones and their potential future role in the treatment of chlamydial respiratory infections. Drugs. 1995;49 (Suppl 2):257-259.
29. Kaku M, Ishida K, Irifune K, et al. In vitro and in vivo activities of sparfloxacin against Mycoplasma pneumoniae. Antimicrob Agents Chemother. 1994;38:738-741.
30. Bensch G, for the SPAR Multicenter Community Acquired Pneumonia Study Group. Treatment of community acquired pneumonia (CAP) with sparfloxacin and erythromycin. Presented at the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 15-18, 1996; New Orleans, La. Abstract LM12, p 282.
31. Data on file, Rhône-Poulenc Rorer Pharmaceuticals, Inc. Collegeville, Pa, 1994